The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Georges Gebrael
No Relationships to Disclose
 
Yeonjung Jo
No Relationships to Disclose
 
Chadi Hage Chehade
No Relationships to Disclose
 
Zeynep Irem Ozay
No Relationships to Disclose
 
Nicolas Sayegh
No Relationships to Disclose
 
Micah Ostrowski
No Relationships to Disclose
 
Patrick Campbell
No Relationships to Disclose
 
Ethan Anderson
Employment - Huntsman Cancer Institute
 
Blake Nordblad
No Relationships to Disclose
 
Gliceida Galarza Fortuna
No Relationships to Disclose
 
Vinay Mathew Thomas
No Relationships to Disclose
 
Irbaz Riaz
No Relationships to Disclose
 
Ryon Graf
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Avirup Guha
Employment - AstraZeneca (I)
Consulting or Advisory Role - Myovant Sciences; Novartis; Pfizer
Research Funding - Sumitovant Biopharma (Inst)
 
Benjamin Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Lilly; Merck; Peloton Therapeutics; Pfizer; Sanofi; Telix Pharmaceuticals; Tempus; Xencor
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Soumyajit Roy
Employment - Artera (I); Rush University
Research Funding - Swim Across America
 
Emmanuel Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Umang Swami
Consulting or Advisory Role - Adaptimmune; Astellas Pharma; AstraZeneca; Exelixis; Gilead Sciences; Imvax; Janssen Scientific Affairs; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); lava therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst)